Skip to main content
Premium Trial:

Request an Annual Quote

Biosimilars: A Fancy Name for Generics But Oh So Much More Disastrous

Over on VentureBeat, David Hamilton writes that even normally smart biotechnology investors get a little dim when talking about biosimilars and the loss of patent protection for biotech drugs. Steve Burrill, CEO of the life science venture capital firm Burrill & Company, told Fortune magazine that the approval of biosimilars will be "devastating for the industry." Hamilton responds that "if the biotech industry is so delicate that it requires perpetual protection from the cold, cruel winds of competition, it can’t possibly be anywhere near as innovative and revolutionary as it has always claimed."

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.